Stay updated on ABLE: Abraxane + Anti-PD1/PDL1 in Adv Urothelial Cancer Clinical Trial

Sign up to get notified when there's something new on the ABLE: Abraxane + Anti-PD1/PDL1 in Adv Urothelial Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ABLE: Abraxane + Anti-PD1/PDL1 in Adv Urothelial Cancer Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    A new site revision (Revision: v3.4.2) was added, replacing the former v3.4.1 notice. This update appears to be a routine maintenance/version update and does not alter study details, eligibility criteria, or patient information.
    Difference
    0.4%
    Check dated 2026-02-11T02:35:57.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    The page now includes a site-wide notice about government funding and the NIH Clinical Center's status, and the release notes show a revision to v3.4.1 (replacing v3.4.0). These edits are administrative and do not alter the study details, eligibility criteria, interventions, outcomes, or results. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-04T00:01:23.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Added a glossary toggle, updated QC metadata text (capitalization of 'Last Update Submitted that Met QC Criteria'), added 'No FEAR Act Data', and updated the revision to v3.4.0, replacing the previous entries (Last Update Submitted that met QC Criteria, No FEAR Act data, Revision: v3.3.4).
    Difference
    0.2%
    Check dated 2026-01-28T00:16:04.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    Page revision updated from v3.3.3 to v3.3.4. This change does not affect study details, eligibility criteria, outcomes, or other user-facing content; To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-13T18:57:30.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    Locations section now lists Michigan as a study site under Locations. The footer text changed by removing 'HHS Vulnerability Disclosure' and 'Michigan Locations' and the revision tag updated from v3.3.2 to v3.3.3.
    Difference
    0.2%
    Check dated 2025-12-23T07:38:21.000Z thumbnail image
  7. Check
    85 days ago
    Change Detected
    Summary
    A new revision tag v3.3.2 was added and the previous v3.3.1 tag removed, indicating a minor version update with no changes to study details. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-12-01T16:27:44.000Z thumbnail image

Stay in the know with updates to ABLE: Abraxane + Anti-PD1/PDL1 in Adv Urothelial Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ABLE: Abraxane + Anti-PD1/PDL1 in Adv Urothelial Cancer Clinical Trial page.